217 related articles for article (PubMed ID: 31218578)
1. Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients.
Jiang HJ; Wang XX; Luo BF; Cong X; Jin Q; Qin H; Zhang HY; Kong XS; Wei L; Feng B
Clin Exp Med; 2019 Aug; 19(3):299-308. PubMed ID: 31218578
[TBL] [Abstract][Full Text] [Related]
2. Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir.
Wang XX; Luo BF; Jiang HJ; Cong X; Jin Q; Ma DL; Wei L; Feng B
World J Gastroenterol; 2018 Oct; 24(40):4554-4564. PubMed ID: 30386105
[TBL] [Abstract][Full Text] [Related]
3. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C.
Nattermann J; Feldmann G; Ahlenstiel G; Langhans B; Sauerbruch T; Spengler U
Gut; 2006 Jun; 55(6):869-77. PubMed ID: 16322112
[TBL] [Abstract][Full Text] [Related]
4. Association of NKG2A with treatment for chronic hepatitis C virus infection.
Harrison RJ; Ettorre A; Little AM; Khakoo SI
Clin Exp Immunol; 2010 Aug; 161(2):306-14. PubMed ID: 20550548
[TBL] [Abstract][Full Text] [Related]
5. The effects of direct-acting antiviral agents on the frequency of myeloid-derived suppressor cells and natural killer cells in patients with chronic hepatitis C.
Li Y; Zeng Y; Zeng G; Li J; Zhang X; Cai Q; Chen Y; Lin CS
J Med Virol; 2019 Feb; 91(2):278-286. PubMed ID: 30171691
[TBL] [Abstract][Full Text] [Related]
6. [Effect of gMDSCs on natural killer cell functionality in chronic hepatitis C patients treated with direct-acting antiviral agents].
Shi JJ; Zhou WJ; Lu C; Jia XY; Chang WX; Zhang JY; Li YY; Mu XL
Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(27):2133-2139. PubMed ID: 34275248
[No Abstract] [Full Text] [Related]
7. Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy.
Perpiñán E; Pérez-Del-Pulgar S; Londoño MC; Mariño Z; Bartres C; González P; García-López M; Pose E; Lens S; Maini MK; Forns X; Koutsoudakis G
Front Immunol; 2020; 11():129. PubMed ID: 32161581
[No Abstract] [Full Text] [Related]
8. Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis.
Krämer B; Körner C; Kebschull M; Glässner A; Eisenhardt M; Nischalke HD; Alexander M; Sauerbruch T; Spengler U; Nattermann J
Hepatology; 2012 Oct; 56(4):1201-13. PubMed ID: 22532190
[TBL] [Abstract][Full Text] [Related]
9. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.
Serti E; Chepa-Lotrea X; Kim YJ; Keane M; Fryzek N; Liang TJ; Ghany M; Rehermann B
Gastroenterology; 2015 Jul; 149(1):190-200.e2. PubMed ID: 25754160
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
[TBL] [Abstract][Full Text] [Related]
11. Functional Behavior of NKp46-Positive Intrahepatic Natural Killer Cells Against Hepatitis C Virus Reinfection After Liver Transplantation.
Tanimine N; Tanaka Y; Abe T; Piao J; Chayama K; Ohdan H
Transplantation; 2016 Feb; 100(2):355-64. PubMed ID: 26714120
[TBL] [Abstract][Full Text] [Related]
12. HBsAg stimulates NKG2D receptor expression on natural killer cells and inhibits hepatitis C virus replication.
Wang XX; Pan XB; Han JC; Cong X; Jin Q; Kong XS; Wei L; Feng B
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):233-240. PubMed ID: 29625837
[TBL] [Abstract][Full Text] [Related]
13. Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.
Spaan M; van Oord G; Kreefft K; Hou J; Hansen BE; Janssen HL; de Knegt RJ; Boonstra A
J Infect Dis; 2016 Jan; 213(2):216-23. PubMed ID: 26223768
[TBL] [Abstract][Full Text] [Related]
14. Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
Johnson SW; Davis MM; Stever LM; Priest DH
J Clin Pharm Ther; 2016 Dec; 41(6):727-729. PubMed ID: 27670742
[TBL] [Abstract][Full Text] [Related]
15. High frequencies of CD158b+ NK cells are associated with persistent hepatitis C virus infections.
Ji HF; Wang J; Yu L; Niu JQ; Ayana DA; Jiang YF
Ann Hepatol; 2013; 12(4):539-47. PubMed ID: 23813131
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy.
Spaan M; van Oord GW; Janssen HL; de Knegt RJ; Boonstra A
Antiviral Res; 2015 Nov; 123():86-92. PubMed ID: 26363298
[TBL] [Abstract][Full Text] [Related]
17. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
18. Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients.
Mele D; Oliviero B; Mantovani S; Ludovisi S; Lombardi A; Genco F; Gulminetti R; Novati S; Mondelli MU; Varchetta S
Hepatology; 2021 Jan; 73(1):79-90. PubMed ID: 32281670
[TBL] [Abstract][Full Text] [Related]
19. Frequency and role of NKp46 and NKG2A in hepatitis B virus infection.
Yoshioka T; Tatsumi T; Miyagi T; Mukai K; Nishio K; Nishio A; Yokoyama Y; Suda T; Kegasawa T; Shigekawa M; Hikita H; Sakamori R; Takehara T
PLoS One; 2017; 12(3):e0174103. PubMed ID: 28328926
[TBL] [Abstract][Full Text] [Related]
20. Effect of Combined HCV Therapy on Natural Killer Cell Activity.
Abd-Elsamie E; Kamal-ElDin TM; Hassaballa AE; A M; Badawy ER; ElMelegy TT; Zahran AM; Mekky MA
Egypt J Immunol; 2019 Jan; 26(1):151-161. PubMed ID: 31333005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
